Snake venom has given modern medicine at least half a dozen drugs, ranging from one of the world’s most prescribed blood-pressure medications to antiplatelet agents used during heart procedures and experimental painkillers that rival morphine. The path from deadly bite to pharmacy shelf is one of the more surprising stories in drug development. What makes it especially interesting is that researchers keep finding new therapeutic leads in venom, even decades after the first breakthrough.
Captopril and the Birth of ACE Inhibitors
The drug that launched the entire field of venom-derived medicine is captopril, approved in 1981 for high blood pressure and heart failure. Its origin traces back to the Brazilian pit viper, Bothrops jararaca. In the 1960s, a Brazilian scientist named Sérgio Ferreira noticed that the viper’s venom contained peptides that caused a dramatic drop in blood pressure by blocking an enzyme called angiotensin-converting enzyme, or ACE. That enzyme normally tightens blood vessels and raises blood pressure. Block it, and pressure falls.
Researchers at the pharmaceutical company Squibb took those venom peptides and used them as a blueprint to design a small, orally active molecule that could do the same thing without injecting anyone with snake proteins.1Ovid / Lippincott Williams & Wilkins (Hypertension). History of the design of captopril and related inhibitors of angiotensin converting enzyme The result was captopril, which became the prototype for an entire class of drugs now called ACE inhibitors. Today that class includes lisinopril, enalapril, and ramipril, all descendants of the same venom-inspired insight. Hundreds of millions of prescriptions are written for ACE inhibitors each year worldwide. None of them contain actual venom, but none of them would exist without it.
Tirofiban, the First Antiplatelet Drug from Venom
After captopril proved that snake venom could inspire blockbuster drugs, researchers started looking more carefully at what else venom proteins could do. One finding that stood out was the ability of certain venom components called disintegrins to interfere with blood clotting by blocking the receptors on platelets that allow them to clump together.
The first antiplatelet drug developed from a snake venom protein was tirofiban, sold under the brand name Aggrastat. It was designed based on a protein called echistatin, first isolated in 1988 from the venom of the saw-scaled viper (Echis carinatus). Echistatin turned out to be a powerful blocker of fibrinogen-induced platelet clumping.2PubMed Central. From Snake Venom’s Disintegrins and C-Type Lectins to Anti-Platelet Drugs – Section: Tirofiban (Aggrastat) Tirofiban is not a peptide itself but a small synthetic molecule modeled on the key recognition sequence in echistatin. It is used intravenously in hospitals to prevent blood clots during and after procedures like angioplasty in patients with acute coronary syndromes.
The saw-scaled viper is one of the most medically significant snakes in the world, responsible for more snakebite deaths than almost any other species across South Asia and the Middle East. The irony that a component of its venom now saves lives in cardiac units is not lost on venom researchers.
Eptifibatide and the Pygmy Rattlesnake Connection
Shortly after tirofiban, a second venom-derived antiplatelet drug reached the market: eptifibatide, sold as Integrilin. This one traces to a different snake entirely, the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). A disintegrin protein called barbourin was isolated from its venom and found to contain an unusual amino acid sequence (KGD instead of the more common RGD) that gave it high selectivity for the platelet receptor involved in clotting.
Researchers synthesized a series of cyclic peptides based on that KGD sequence, systematically tweaking the ring size and other chemical features until they arrived at eptifibatide, a cyclic heptapeptide that competitively blocks the activated platelet receptor with potency and selectivity comparable to the original venom protein.3MDPI. From Snake Venom’s Disintegrins and C-Type Lectins to Anti-Platelet Drugs – Section: Eptifibatide (Integrilin) Like tirofiban, eptifibatide is given intravenously in hospital settings, typically during percutaneous coronary interventions and in the management of unstable angina. Both drugs have been used in millions of patients since their approval in the late 1990s.
Batroxobin for Blood Clots and Stroke
Not all venom-derived drugs work by stopping clots. Some work by dissolving them. Batroxobin is a thrombin-like enzyme originally isolated from the venom of the South American lance-headed viper (Bothrops atrox, among related species). It has an unusual property: it selectively cleaves fibrinogen in the blood, which lowers the concentration of the clotting protein and promotes the body’s own clot-dissolving processes without causing the kind of uncontrolled bleeding that many anticoagulants risk.
Batroxobin has been investigated for use in deep vein thrombosis and cerebral infarction because it promotes thrombolysis, helps prevent recurrence of blood clots, and appears to offer some degree of neuroprotection.4PubMed Central. Use of Batroxobin in Central and Peripheral Ischemic Vascular Diseases: A Systematic Review It has seen clinical use primarily in parts of Asia and South America, where it is marketed under brand names like Defibrase. Its regulatory status varies by country, and it has not gained widespread approval in the United States or Europe, but the research base around it continues to grow.
The appeal of batroxobin is its selectivity. Traditional anticoagulants like heparin or warfarin affect multiple points in the clotting cascade, which is why they carry a meaningful risk of bleeding complications. Batroxobin’s more targeted mechanism, acting on fibrinogen specifically, gives it a narrower profile. Whether that theoretical advantage translates into consistently better clinical outcomes is something researchers are still sorting out through trials.
Ancrod and the Malayan Pit Viper
Ancrod is another defibrinogenating agent, this one derived from the venom of the Malayan pit viper (Calloselasma rhodostoma). Like batroxobin, it works by breaking down fibrinogen, effectively thinning the blood by depleting one of the key raw materials for clot formation. Ancrod attracted particular attention for its potential in treating acute ischemic stroke, the type caused by a blood clot blocking an artery in the brain.
A major randomized controlled trial called STAT (Stroke Treatment with Ancrod Trial) evaluated intravenous ancrod in patients with acute ischemic stroke to see whether rapid defibrinogenation could improve outcomes.5JAMA. Intravenous Ancrod for Treatment of Acute Ischemic Stroke: The STAT Study: A Randomized Controlled Trial The trial showed some early promise, but follow-up studies and regulatory hurdles meant that ancrod never achieved broad clinical adoption. It remains an interesting case study in venom pharmacology: a drug that works through a genuinely novel mechanism but struggled to find its place in a treatment landscape increasingly dominated by tissue plasminogen activator (tPA) for stroke.
Ancrod also illustrates a broader pattern in venom drug development. Many venom-derived compounds show real biological activity and intriguing mechanisms, but converting that into a drug that reliably beats existing options in large trials is a different challenge altogether. The pipeline from venom to approved medicine is littered with candidates that worked in principle but could not clear the clinical bar.
Mambalgins and the Search for Non-Opioid Pain Relief
One of the most exciting recent discoveries in venom pharmacology comes from an unexpected source: the black mamba (Dendroaspis polylepis), widely feared as one of the fastest and most dangerous snakes on Earth. In 2012, French researchers identified two peptides from black mamba venom that they named mambalgins. These peptides abolished pain in animal models by blocking specific acid-sensing ion channels expressed in both central and peripheral neurons.
The analgesic effect was striking. Upon both central and peripheral injection, mambalgins produced pain relief as strong as morphine, but without the tolerance that makes opioids progressively less effective over time.6Nature. Black mamba venom peptides target acid-sensing ion channels to abolish pain In a world grappling with opioid addiction and overdose deaths, a painkiller that matches morphine’s potency through a completely different mechanism is a finding that gets people’s attention. Mambalgins are not yet a drug you can take, but they identified acid-sensing ion channels as a viable therapeutic target for pain and opened a new line of drug development that sidesteps the opioid receptor entirely.
The road from mambalgins in a lab to something a patient can actually use remains long. Peptide drugs face challenges with delivery (they tend to break down in the gut, ruling out oral pills), stability, and manufacturing cost. But several research groups are working on modified versions and delivery strategies. Even if mambalgins themselves never become a commercial product, the mechanism they revealed could inspire a new class of painkillers designed around the same ion channel targets.
Why Venom Is Such a Rich Source of Drug Leads
It is reasonable to wonder why snake venom, of all things, keeps producing useful medicines. The answer has to do with evolution. Venomous snakes have been refining their venoms for tens of millions of years under intense selective pressure. A venom that does not effectively immobilize prey means the snake goes hungry. That pressure has produced an extraordinary diversity of bioactive molecules, each finely tuned to interact with specific receptors, enzymes, and ion channels in animal physiology.
Those same receptors and channels exist in humans. A venom protein that blocks a clotting receptor in a mouse to cause hemorrhage can, in a purified and controlled dose, become an antiplatelet drug. A peptide that disrupts nerve signaling to paralyze prey can, at the right dose and target, become a painkiller or a treatment for neurological disease. The venom did not evolve to be medicine, but evolution made it exquisitely targeted, and that targeting is exactly what drug designers need.
Snake venoms also tend to contain not just one or two but dozens to hundreds of distinct peptides and proteins. Each species has a different cocktail, and even individuals within the same species can show variation in their venom composition depending on geography, diet, and age. The total library of venom compounds across the roughly 700 venomous snake species is enormous, and only a fraction has been characterized in detail. Researchers estimate that venom-derived drug discovery has barely scratched the surface of what is available.
How Venom-Derived Drugs Are Actually Made
A common misconception is that producing these drugs requires milking snakes on an industrial scale. That may have been partly true in the early research stages, when scientists needed raw venom to identify and isolate the active compounds. But every approved venom-derived drug on the market today is made synthetically or through recombinant biotechnology. Captopril is a small molecule synthesized through standard chemical processes. Eptifibatide is a synthetic peptide. Tirofiban is a synthetic non-peptide molecule. None of them require a single snake.
This is an important distinction. The snake provides the blueprint, not the manufacturing line. Once researchers identify a venom peptide with a useful biological activity, they determine its chemical structure, figure out which part of the molecule is responsible for the effect, and then either synthesize it directly or design a simplified version that keeps the activity while being easier and cheaper to produce. The final product bears no biochemical resemblance to crude venom any more than aspirin resembles willow bark.
For researchers still in the discovery phase, venom collection does remain part of the process. Herpetology labs and venom institutes around the world maintain colonies of venomous snakes for this purpose, using standardized milking techniques to extract small quantities of venom for analysis. Some facilities have built venom libraries containing samples from hundreds of species, creating a kind of natural pharmacy that researchers can screen for new drug leads.
Drugs from Other Venomous Animals
Snake venom gets the most attention in this space, but it is not the only animal venom that has produced approved medicines. Ziconotide (brand name Prialt) is a pain drug derived from the venom of the cone snail, Conus magus. It blocks a specific type of calcium channel in the spinal cord and is approved for severe chronic pain in patients who have not responded to other treatments. It is delivered through an intrathecal pump directly into the spinal fluid, which gives you a sense of how specialized its use is.
Exenatide (brand name Byetta) comes from the saliva of the Gila monster, a venomous lizard found in the American Southwest. Gila monster saliva contains a peptide called exendin-4 that mimics a human hormone involved in blood sugar regulation. Exenatide became one of the first GLP-1 receptor agonists approved for type 2 diabetes and helped pave the way for the broader GLP-1 drug class that now includes liraglutide and semaglutide. The explosion of interest in GLP-1 drugs for diabetes and weight management traces part of its lineage to a desert lizard’s venomous bite.
Scorpion venom, spider venom, and bee venom are all under active investigation as well. A fluorescent peptide derived from scorpion venom called tumor paint is being studied for its ability to bind to cancer cells and make them visible during surgery. Spider venom peptides are being explored for their effects on ion channels relevant to epilepsy and chronic pain. The broader principle is the same: evolution has spent millions of years engineering molecules that interact powerfully with biological targets, and drug hunters are learning to read that engineering.
What Is Still in the Pipeline
Beyond mambalgins, several other snake venom compounds are in various stages of preclinical and early clinical development. Researchers are investigating venom-derived peptides for conditions including cancer, autoimmune disease, and antimicrobial resistance. Some snake venom components show potent antibacterial activity against drug-resistant organisms, a finding that has attracted interest given the growing threat of antibiotic resistance worldwide.
Others are looking at venom compounds that affect blood vessel growth. Certain venom proteins can inhibit angiogenesis, the formation of new blood vessels that tumors need to grow and spread. If these can be refined into drugs with acceptable safety profiles, they could join the existing class of anti-angiogenic cancer therapies. The challenge, as always, is moving from a promising venom peptide to something that works safely in humans at a dose you can deliver reliably.
One area generating particular interest is the use of venom peptides as molecular tools to understand disease mechanisms, even when the peptide itself will never become a drug. Mambalgins, for instance, may matter more for what they revealed about acid-sensing ion channels as pain targets than for their own drugability. In this way, venom serves double duty: some compounds become medicines directly, while others become keys that unlock new understanding of how diseases work at the molecular level, pointing the way for entirely synthetic drugs designed from scratch.